Protein kinase C pathway is involved in transcriptional regulation of C-reactive protein synthesis in human hepatocytes

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 25, Issue 1, 2005, Pages 186-192

  Ivashchenko, Yuri ^a   Kramer, Frank ^a   Schäfer, Stefan ^a   Bucher, Andrea ^b   Veit, Kerstin ^a   Hombach, Vinzenz ^b   Busch, Andreas ^a   Ritzeler, Olaf ^a   Dedio, Jürgen ^a   Torzewski, Jan ^b  

^a SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

Atherosclerosis; C reactive protein; Drug development; Gene expression; Protein kinase C

Indexed keywords

BISINDOLYLMALEIMIDE; C REACTIVE PROTEIN; I 229; I KAPPA B KINASE INHIBITOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; PHORBOL DIBUTYRATE; PROTEIN KINASE C; RUBOXISTAURIN; UNCLASSIFIED DRUG;

ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENETIC TRANSFECTION; HEPATOMA CELL; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; LIVER CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION;

AORTA; C-REACTIVE PROTEIN; CARCINOMA, HEPATOCELLULAR; CELL LINE; CELL LINE, TUMOR; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HEPATOCYTES; HUMANS; INTERLEUKIN-1; INTERLEUKIN-6; INTERLEUKIN-8; LIVER NEOPLASMS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PHORBOL 12,13-DIBUTYRATE; PROMOTER REGIONS (GENETICS); PROTEIN KINASE C; TRANSCRIPTION, GENETIC; UMBILICAL VEINS;

EID: 19944426602     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000150041.81963.68     Document Type: Article

References (39)

1. Mortensen RF. C-reactive protein, inflammation, and innate immunity. Immunol Res. 2001;24:163-176.
2. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet. 1997;349:462-466.
3. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843.
4. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557-1156.
5. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-1397.
6. Torzewski J, Torzewski M, Bowyer DE, Frohlich M, Koenig W, Waltenberger J, Fitzsimmons C, Hombach V. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol. 1998;18:1386-1392.
7. Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol. 2001;158:1039-1051.
8. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000;102:2165-2168.
9. Pasceri V, Cheng JS, Willerson JT, Yeh ET, Chang J. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation. 2001;103:2531-2534.
10. Sternik L, Samee S, Schaff HV, Zehr KJ, Lerman LO, Holmes DR, Herrmann J, Lerman A. C-reactive protein relaxes human vessels in vitro. Arterioscler Thromb Vasc Biol. 2002;22:1865-1868.
11. Hattori Y, Matsumura M, Kasai K. Vascular smooth muscle cell activation by C-reactive protein. Cardiovasc Res. 2003;58:186-195.
12. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages. Circulation. 2001;103:1194-1197.
13. Bhakdi S, Torzewski M, Paprotka K, Schmitt S, Barsoom H, Suriyaphol P, Han SR, Lackner KJ, Husmann M. Possible protective role for C-reactive protein in atherogenesis: complement activation by modified lipoproteins halts before detrimental terminal sequence. Circulation. 2004;109:1870-1876.
14. Paul A, Ko WS, Li L, Yechoor V, McCrory MA, Szalai AJ, Chan L. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2004;109:647-655.
15. Kleeman R, Verschuren L, de Rooij BJ, Lindemann J, de Maat MM, Szalai AJ, Princen HM, Kooistra T. Evidence for anti-inflammatory activity of statins and PPARα activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Blood. 2004;103:4188-4194.
16. Calabro P, Willerson JT, Yeh ET. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation. 2003;108:1930-1932.
17. Gomez-Lechon MJ, Donato MT, Castell JV, Jover R. Human hepatocytes as a tool for studying toxicity and drug metabolism. Curr Drug Metab. 2003;4:292-312.
18. Toniatti C, Demartis A, Monaci P, Nicosia A, Ciliberto G. Synergistic transactivation of the human C-reactive protein promoter by transcription factor HNF-1 binding at two distinct sites. EMBO J. 1990;9:4467-4475.
19. Majello B, Arcone R, Toniatti C, Ciliberto G. Constitutive and IL-6 induced nuclear factors that interact with the human C-reactive protein promoter. EMBO J. 1990;9:457-465.
20. Taylor AW, Ku NO, Mortensen RF. Regulation of cytokine-induced human C-reactive protein production by transforming growth factor-beta. J Immunol. 1990;145:2507-2513.
21. Li SP, Goldmann ND. Regulation of human C-reactive protein gene expression by two synergistic IL-6 responsive elements. Biochemistry. 1996;35:9060-9068.
22. Zhang D, Sun M, Samols D, Kushner I. STAT3 participates in transcriptional activation of the C-reactive protein gene by interleukin-6. J Biol Chem. 1996;271:9503-9509.
23. Kleemann R, Gervois PP, Verschuren L, Staels B, Princen HM, Kooistra T. Fibrates downregulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFκB-C/EBP-β complex formation. Blood. 2003;101:545-551.
24. Ghosh S, Karin M. Missing pieces in the NF-κB puzzle. Cell. 2002;109:81-96.
25. Su TT, Guo B, Kawakami Y, Sommer K, Chae K, Humphries LA, Kato RM, Kang S, Patrone L, Wall R, Teitell M, Leitges M, Kawakami T, Rawlings DJ. PKC-β controls IκB kinase lipid raft recruitment and activation in response to BCR signaling. Nat Immunol. 2002;3:780-786.
26. Moscat J, Diaz-Meco MT, Rennert P. NFκB activation by protein kinase C isoforms and B-cell function. EMBO Rep. 2003;4:31-36.
27. Nishizuka Y. The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature. 1988;334:661-665.
28. Trautwein C, Caelles C, van der Geer P, Hunter T, Karin M, Chojkier M. Transactivation by NF-IL6/LAP is enhanced by phosphorylation of its activation domain. Nature. 1993;364:544-547.
29. Ritzeler O, Stilz U, Neises B, Jaehne G, Habermann J. Benzimidazoles. German Patent No. DE19928424-A1; 2000.
30. Jirousek MR, Gillig JR, Gonzalez CM, Heath WF, McDonald JH, Neel D, Rito CJ, Singh U, Stramm LE, Melikian-Badalian A, Baevsky M, Ballas LM, Hall SE, Winneroski LL, Faul MM. S)-13-[(Dimethylamino)methyl]-10,11,14,15-tetrahydro-4, 9:16,21-dimetheno-1H,13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxa- diazacyclohexadecene-1,3(2H)-dione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase Cβ. J Med Chem. 1996;39:2664-2671.
31. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000;35:95-105.
32. Matthews V, Schuster B, Schütze S, Bussmeyer I, Ludwig A, Hundhausen C, Sadowski T, Saftig P, Hartmann D, Kallen KJ, Rose-John S. Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). J Biol Chem. 2003;278:38829-38839.
33. Manolov DE, Koenig W, Hombach V, Torzewski J. C-reactive protein and atherosclerosis-is there a causal link? Histol Histopathol. 2003;18:1189-1193.
34. Manolov DE, Roecker C, Hombach V, Nienhaus GU, Torzewski J. Ultrasensitive confocal fluorescence microscopy of C-reactive protein interacting with FcγRIIa. Arterioscler Thromb Vasc Biol. 2004;24:2372-2377.
35. Maekawa H, Tollefsen DM. Role of proposed serpin-enzyme complex receptor recognition sites in binding and internalization of thrombin-heparin cofactor II complexes by hepatocytes. J Biol Chem. 1996;271:18604-18609.
36. Wigmore SJ, Fearon KC, Maingay JP, Lai PB, Ross JA. Interleukin-8 can mediate acute-phase protein production by isolated human hepatocytes. Am J Physiol. 1997;273:720-726.
37. Boisvert WA. Modulation of atherogenesis by chemokines. Trends Cardiovasc Med. 2004;14:161-165.
38. Jabs WJ, Logering BA, Gerke P, Kreft B, Wolber EM, Klinger MH, Fricke L, Steinhoff J. The kidney as a second site of human C-reactive protein formation in vivo. Eur J Immunol. 2003;33:152-161.
39. Ciliberto G, Arcone R, Wagner EF, Ruther U. Inducible and tissue-specific expression of human C-reactive protein in transgenic mice. EMBO J. 1987;6:4017-4022.